ConcertAI has entered a multi-year agreement with Bayer to accelerate clinical development in precision oncology using ConcertAI’s Translational360™ platform, powered by Guardant Health’s liquid biopsy genomic data and AI-driven SaaS solutions.

Translational360™ is an integrated, research-grade clinical molecular database that draws from over 9 million de-identified cancer patient records in the CancerLinQ network, spanning all 50 U.S. states. This platform merges clinical, genomic, transcriptomic, and whole-slide imaging data to offer deep phenotypic and molecular insights essential for advancing oncology research and development.

Transcriptomics, a key element of Translational360™, allows researchers to investigate disease mechanisms, patient responses, and variability—crucial for identifying promising therapeutic candidates. By integrating multi-modal data with AI/ML insights, the platform addresses the ambiguity often found in early-phase trials and informs trial design and program prioritization with a higher likelihood of success.

“This partnership enhances causal biological inferences and supports discovery through clinical development by applying AI to multi-dimensional data,” said Jeff Elton, Ph.D., CEO of ConcertAI. “It uniquely leverages both tissue and liquid biopsy data for deeper insights into treatment response and resistance.”

Guardant Health’s Helmy Eltoukhy highlighted how real-world data unlocks comprehensive insights into tumor biology and patient responses, helping guide critical decisions in targeted therapy development. Sai Jasti of Bayer emphasized the importance of combining real-world data with AI to accelerate drug discovery and bring innovative treatments to patients more rapidly.

Claudio D’Ambrosio, Ph.D., Chief Revenue Officer at ConcertAI, noted that this approach reverses traditional R&D models by beginning with human cancer data instead of preclinical models. “We now have access to powerful human data, allowing us to flip the paradigm and improve the precision and speed of oncology drug development.”

Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin) has achieved 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation across all its greenfield labs.

“This accreditation is a testament to the team's dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics,” said Ravindra Kumar, CEO, Lupin Diagnostics. “We remain committed to enhancing healthcare through continuous improvement and innovation.”

This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services. The company’s commitment to quality is reflected in every aspect of its operations, ensuring patients receive accurate and timely results that they can trust.

Among its recent accolades, Lupin Diagnostics received the prestigious titles of ‘Patient-Centric Diagnostic Laboratories Company of the Year’ at the IHW 3rd Patients First Award 2024, ‘Emerging Diagnostics Chain of the Year’ at the Diagnostics Innovation and Excellence Award 2024 by Voice of Healthcare, and ‘Pathology Lab of the Year’ (National Category) at the ET Healthcare Awards in 2022 and 2024. These honors emphasize the company's dedication to patient-centered care and its leading position in the diagnostics industry.

In collaboration with CanSupport, a WHO-recognised NGO, Cipla Foundation has launched a comprehensive palliative home care initiative in Pune, offering free-of-charge services to cancer patients. This new program, powered by nine dedicated home care teams, aims to reach over 900 patients across five talukas in Pune District—Pune City, Haveli, Khed, Bhor, and Purandar.

CanSupport has over 28 years of experience delivering home-based palliative care and brings its well-established, interdisciplinary model to the partnership. The service focuses on patients with advanced cancer, complex symptoms, mobility challenges, or those discharged from the Cipla Palliative Care and Training Centre (CPC) in Pune who require continued support. While the majority of beneficiaries are oncology patients, around 10% live with non-cancer conditions such as chronic respiratory or neurological illnesses.

The initiative provides a full spectrum of care, including pain management, wound care, physiotherapy, counselling, and access to assistive devices like wheelchairs, water beds, and walkers. Importantly, the teams also guide families in caregiving strategies and decision-making, ensuring emotional and psychosocial support is integrated alongside medical care.

An outpatient Pain and Palliative Care Clinic further complements the home visits, offering continuity of care and additional resources for patients and families.

Anurag Mishra, Head of Cipla Foundation, remarked, “By bringing palliative care directly to patients’ homes, we aim to reduce suffering, preserve dignity, and support families through their difficult times.”

Dr Ambika Rajvanshi, CEO of CanSupport, added, “Our model addresses both the medical and emotional needs of patients and families, offering holistic, compassionate care.”

Designed as a replicable model for other cities, the Pune program showcases the potential of community-based palliative care to improve quality of life for patients and their families.

BPL Medical Technologies Pvt. Ltd., a leading Indian medical device company, has announced significant leadership transitions as part of its strategic growth plan. Mr. Sunil Khurana, the founding CEO and Managing Director, has been promoted to Executive Chairman. Dr. Shravan Subramanyam has been appointed as the new Managing Director of BPL MedTech and Group CEO of the Claypond Capital-backed MedTech platform. Additionally, Mr. Guruswamy Krishnamoorthy, currently the COO, will take over as CEO of BPL Medical Technologies effective April 1, 2025.

Since founding BPL MedTech in 2013, Mr. Khurana has played a key role in building the company into a trusted name in India’s medical devices sector. He led the company’s expansion, including establishing a second manufacturing facility in Bengaluru to enhance production capacity. In his new role, he will focus on shaping the strategic direction of the company, mentoring leadership, and ensuring alignment with long-term goals.

Dr. Subramanyam, a third-generation physician from Madras Medical College, brings over 20 years of healthcare experience, having held leadership roles at Wipro-GE Healthcare, Roche, and Novartis. He has also driven investment strategies at Premji Invest and Claypond Capital. As MD and Group CEO, he will lead the company into its next growth phase, BPL 2.0, aiming to expand its impact globally.

Mr. Krishnamoorthy joined BPL MedTech in 2017 and has led key international and strategic business efforts. He also served as CEO of Penlon Ltd., a former BPL MedTech company in the UK, where he earned the title of MBE from Queen Elizabeth II for his leadership during the COVID-19 crisis. As the new CEO, he will oversee day-to-day operations and execute the company’s strategic roadmap.

BPL Medical Technologies, headquartered in Bengaluru, operates 14 branch offices and has a network of over 600 professionals. The company specializes in cardiology, critical care, imaging, and home care equipment. Its ISO-certified facilities in Palakkad and Bengaluru are equipped to deliver high-quality products, with the Bengaluru facility inaugurated by Prime Minister Narendra Modi in October 2024 under the Government of India’s PLI initiative.

The Employees' State Insurance Corporation (ESIC) is set to expand its healthcare reach by establishing 10 new medical colleges across India. These institutions are proposed in Pune, Manesar, Kollam, Surat, Visakhapatnam, Bhubaneshwar, Asansol, Nagpur, Pandunagar, and Margaon, as announced by Union Labour Minister Mansukh Mandaviya. This expansion aims to improve medical services for ESIC subscribers, especially in unserved and underserved regions.

These new colleges are in addition to the already approved institutions in Andheri, Basaidarapur, Guwahati-Beltola, Indore, Jaipur, Ludhiana, Naroda-Bapunagar, Noida, Varanasi, and Ranchi. The decision was approved in principle during ESIC’s 194th meeting.

To enhance accessibility, ESIC is also working on aligning its healthcare services with the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). This integration will provide comprehensive, cashless medical care to over 14.4 crore beneficiaries. ESIC subscribers will be able to receive treatment at PMJAY-empanelled hospitals without any expenditure cap.

Additionally, ESIC is developing a policy to deliver medical services through Primary Health Centres (PHCs) and Community Health Centres (CHCs) in districts where ESIC implementation is either partial or absent. This move will ensure broader access to healthcare for eligible beneficiaries in these areas.

Since 2014, the ESIC scheme has grown significantly—from 393 districts to 691 as of April 21, 2025. Of these, 592 are fully notified, 99 are partially notified, and 87 districts are yet to be covered. Recently, the scheme was extended to eight districts in Nagaland and 15 in Uttar Pradesh, benefiting an additional 76,274 insured persons and their families. Proposals are also underway to notify further districts in Odisha, Uttar Pradesh, Maharashtra, and Bihar.

The Employees' State Insurance Corporation (ESIC) is set to expand its healthcare reach by establishing 10 new medical colleges across India. These institutions are proposed in Pune, Manesar, Kollam, Surat, Visakhapatnam, Bhubaneshwar, Asansol, Nagpur, Pandunagar, and Margaon, as announced by Union Labour Minister Mansukh Mandaviya. This expansion aims to improve medical services for ESIC subscribers, especially in unserved and underserved regions.

These new colleges are in addition to the already approved institutions in Andheri, Basaidarapur, Guwahati-Beltola, Indore, Jaipur, Ludhiana, Naroda-Bapunagar, Noida, Varanasi, and Ranchi. The decision was approved in principle during ESIC’s 194th meeting.

To enhance accessibility, ESIC is also working on aligning its healthcare services with the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). This integration will provide comprehensive, cashless medical care to over 14.4 crore beneficiaries. ESIC subscribers will be able to receive treatment at PMJAY-empanelled hospitals without any expenditure cap.

Additionally, ESIC is developing a policy to deliver medical services through Primary Health Centres (PHCs) and Community Health Centres (CHCs) in districts where ESIC implementation is either partial or absent. This move will ensure broader access to healthcare for eligible beneficiaries in these areas.

Since 2014, the ESIC scheme has grown significantly—from 393 districts to 691 as of April 21, 2025. Of these, 592 are fully notified, 99 are partially notified, and 87 districts are yet to be covered. Recently, the scheme was extended to eight districts in Nagaland and 15 in Uttar Pradesh, benefiting an additional 76,274 insured persons and their families. Proposals are also underway to notify further districts in Odisha, Uttar Pradesh, Maharashtra, and Bihar.

Clarivate Plc , a global leader in transformative intelligence, has announced the launch of DRG Commercial Analytics 360, an innovative solution designed to help medtech companies drive commercial success through data-driven insights. As the need for precision in strategy and execution continues to rise, this platform provides deeper visibility into customer activity, practice behavior, caseloads, and affiliations—empowering commercial teams to effectively navigate the complex U.S. provider landscape.

Built specifically for the medtech industry, DRG Commercial Analytics 360 merges the robust search capabilities of Procedure Finder with Clarivate’s extensive provider and affiliations network. This integration delivers real-world intelligence that enhances strategic planning, field sales effectiveness, and market execution. The platform offers granular, actionable insights to optimize omnichannel targeting and support smarter commercial decisions.

Juliane Ray, Vice President of Product Management for Medtech, Life Sciences & Healthcare at Clarivate, emphasized the platform's impact: “DRG Commercial Analytics 360 was created to help medtech companies transform real-world data into smarter, more agile strategies. By supporting seamless integration and intelligent bundling, the platform enables precision targeting and improved patient access. With insights at the market segment level, users can discover new opportunities and make confident, data-driven decisions.”

Theo McCormick, Senior Manager of Pricing & Analytics at Bioventus, Inc., added, “The data is reshaping our strategy. Instead of focusing solely on competitors, we now view clinicians more holistically. These insights are enabling more meaningful conversations with physicians and healthcare system leaders.”

Key capabilities of DRG Commercial Analytics 360 include:

• Actionable Intelligence: Integrated data reveals who is treating specific patient groups, their affiliations, and procedural locations across care settings like hospitals and ambulatory surgery centers.

• Accurate Market Segmentation: By eliminating code-level duplication, the platform ensures clarity and consistency in tracking procedure volumes across the U.S.

• 360˚ Market Visibility: Market sizing and resource allocation are enhanced with modularized claims and code groupings aligned to defined market segments.

• Expert-Led Insights: Clarivate’s in-house experts in medtech, coding, and U.S. healthcare apply specialized methodologies to extract nuanced, actionable market intelligence.

This new offering positions Clarivate as a pivotal enabler of growth for medtech companies seeking to optimize performance and patient outcomes through strategic data application.

Molbio Diagnostics Limited, a pioneer in point-of-care molecular diagnostics, recently unveiled their latest innovation, Truenat® HPV-HR Plus, which enables expanded high-risk genotype detection. The chip-based RT-PCR test allows rapid and decentralized detection of eight high-risk genotypes of human papillomavirus (HPV) – which account for over 96% of cervical cancer cases globally. The multicentric validation was supported by the Grand Challenges India, Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Biotechnology (DBT), Government of India under its program “Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India”, making it one of the most trusted, indigenously developed tools for cervical cancer screening in India.

India continues to bear a disproportionate burden of cervical cancer, accounting for nearly 25% of global cases. With more than 1,23,000 new diagnoses and around 77,000 deaths each year, the disease remains the second most common cancer among Indian women — despite being preventable through timely screening.

Highlighting the importance of developing homegrown solutions, Rajesh S. Gokhale, Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India said “Truenat® HPV-HR Plus represents the kind of diagnostic innovation we need — dependable, scientifically rigorous, locally developed, and built to serve our public health system. It’s a huge step forward in strengthening cervical cancer screening across India.”

"Truenat® HPV-HR Plus marks a significant leap in delivering precision diagnostics tailored specifically for the Indian population" said Dr Chandrasekhar Nair, CTO of Molbio Diagnostics Limited. “By including regionally prevalent high-risk HPV genotypes such as HPV 52 and 58, we aim at supporting India's cervical cancer elimination efforts, targeting women’s health in urban and rural areas alike”, he said.

Speaking on the occasion, — Dr. Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC) said, "At BIRAC, we are committed to strengthening India’s health innovation ecosystem by supporting indigenous solutions to pressing public health challenges. The successful validation of Truenat® HPV-HR Plus under our Grand Challenges India initiative marks a significant step toward accessible and accurate cervical cancer screening for women across the country. This test reflects the power of indigenous innovation in advancing early detection and saving lives."

While presenting the evidence gathered during the clinical validation, Dr. Neerja Bhatla, Head of Department, Obstetrics and Gynaecology, AIIMS elaborated upon the high sensitivity and specificity of the test– meeting all parameters of the study.

Truenat® HPV-HR Plus is a simple, fast, and reliable test that checks for high-risk HPV infections using a portable device. Designed to work with cervical swab samples collected by a clinician, it gives highly accurate results in just 60 minutes. Easy to use and with high stability at room temperature, it requires minimal biosafety and  is optimized for use at both the lab and near-patient settings.

On this special occasion, Dr. Madhavi Chandra, who leads Grand Challenges India, emphasized the importance of creating affordable, accurate, and user-friendly diagnostic tools, especially for resource-limited settings. The Truenat® HPV-HR Plus aims to overcome the shortcomings of current diagnostic methods, including high costs, complex workflows, and dependence on advanced equipment. These crucial innovations will benefit women and children in India and around the world.

Fujifilm India, a leader in healthcare technology, has unveiled its cutting-edge ELUXEO 8000 Therapeutic Endoscopy Solution at the 22nd MUMBAI LIVE Endoscopy event, hosted by Sir HN Reliance Foundation Hospital—India’s premier international endoscopy educational forum.

Previously launched in Japan and Europe, the ELUXEO 8000 is now entering the Indian market, poised to elevate endoscopic diagnostics and therapeutic procedures. Designed to improve image quality, streamline workflows, and broaden therapeutic capabilities, the system represents a major leap forward in endoscopic technology.

The ELUXEO 8000 is powered by advanced features such as ACI (Amber-red Color Imaging), TNR (Triple Noise Reduction), and E-DRIP (Extended Dynamic Range Image Processing). These technologies deliver crystal-clear, high-contrast images with reduced halation, empowering clinicians to perform intricate procedures with enhanced precision and confidence.

The solution includes next-generation therapeutic endoscopes, specifically engineered for navigating narrow luminal areas—crucial for complex, minimally invasive treatments. This innovation supports improved outcomes and greater efficiency during challenging interventions.

Koji Wada, Managing Director of Fujifilm India, emphasized the company's mission of “Giving our world more smiles” through innovation. “By delivering cutting-edge healthcare solutions like ELUXEO 8000, we aim to improve access to advanced care and bring joy through better health outcomes.”

Dheeraj Chaudhri, Head of Endoscopy Systems at Fujifilm India, added, “This launch underscores our dedication to providing clinicians with tools that are both technologically advanced and clinically impactful. ELUXEO 8000 redefines the standard for therapeutic endoscopy in India.”

Precision medicine is rapidly emerging as a transformative force in global healthcare, and its growing relevance in India cannot be overstated. This personalized approach to healthcare, which takes into account individual variations in genes, environment, and lifestyle, is reshaping how diseases are diagnosed, treated, and prevented. While India’s precision medicine landscape is still developing, initiatives like the Precision Med India (PMI) Conclave & Awards 2025 are playing a vital role in fostering dialogue, driving innovation, and creating collaborative pathways for its integration into the Indian healthcare system.

The event, held on April 20, 2025, in New Delhi, kicked off with a special address by Shri Ravinder Singh, Hon’ble Minister – Social Welfare, SC & ST Welfare, Cooperative, & Election, Government of Delhi,  He shared his thoughts on the vital role of doctors in society and emphasized the nation’s vision for a healthier, self-reliant India by 2027. Following this, the day began with the Inaugural Address on “Precision Medicine in India: The Road Ahead”, which set an insightful tone for the event. The session featured an elite panel including Dr. Naveen Nishchal, Founding Chairman of Voice of Healthcare; Dr. Simmi Tiwari, Joint Director & Head of the Centre for One Health, National Centre for Disease Control, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; Dr. Divya Khanna, Scientist III at the Institute of Genomics and Integrative Biology, CSIR, New Delhi; Dr. Ravi Gaur, Chairman of the Medical Advisory Committee at Oncquest Laboratories Ltd and Founder & Director of DRG Path Labs; Dr. Upasana Arora, Managing Director of Yashoda Group of Hospitals; and Dr. Amit Jain, President of NIAMBIO. Together, these esteemed experts addressed India’s current precision medicine landscape, highlighting opportunities, challenges, and the need for a collaborative, patient-centric healthcare model.

Dr. Naveen Nishchal spoke about how AI, data, and genomics will transform traditional healthcare into precision-driven, personalized care.

Dr. Nishchal remarked,

“Precision medicine will soon replace traditional healthcare — and AI, data, and genomics together will drive this shift across fields like oncology, cardiology, neurology, and chronic diseases. We stand at the edge of a wave of innovation.”

Dr. Simmi Tiwari highlighted the alignment of precision medicine with India’s One Health initiative and its potential to integrate personal care with public health action.

Dr. Tiwari added,
“Precision medicine, aligned with India’s One Health mission, has the power to transform healthcare by integrating individual-focused care with community-level public health action.”

She further shared,
“I’m grateful to be part of this important conversation on precision medicine, a fast-emerging field that closely aligns with India’s One Health initiative. With dedicated focus areas like enhanced surveillance and outbreak investigations under the National One Health Mission, integrating precision medicine into public health can be a true game-changer — connecting individual-focused care with community-wide health strategies for India’s future.”

Dr. Ravi Gaur emphasized India’s shift from reactive to proactive, value-based care powered by genomics, AI, digital pathology, and centralized health data.

Sharing his thoughts, Dr.Gaur said,
“India is witnessing a shift from reactive to proactive, volume-based to value-based care. Genomics, AI, digital pathology, and centralized health data are key to personalizing patient care at scale — and we need public-private collaborations to get there.”

Dr. Divya Khanna focused on the critical impact of the 0.1% genomic difference in personalizing treatments, advocating for integrated approaches involving genomics, proteomics, and environmental factors.

As the opening address, Dr. Khanna reflected,
“Our mission is to improve patient outcomes by aligning precision interventions with individual biology. While 99.9% of our genome is the same, it’s the 0.1% difference that defines treatment response. By combining genomics, proteomics, metagenomics, and environmental factors, we can build highly targeted, effective care pathways. Platforms like this play a key role in fostering collaboration and translating research into clinical solutions.”
She also noted,
“It’s the 0.1% difference in our genome that makes all the difference. Integrating genomics, proteomics, and epigenetics can help build pipelines for more precise, effective treatments.”

Dr. Upasana Arora stressed the importance of big data and secure, encrypted platforms in enabling precision medicine, along with the emerging relevance of food as medicine.
Dr. Arora emphasized,
“Big data is the backbone of precision medicine. Secure, encrypted platforms like ABDM are vital for sharing actionable data, and concepts like food as medicine are the future of preventive care in India.”

Dr. Amit Jain concluded by highlighting India’s global leadership potential in precision medicine, driven by enhanced NGS, AI diagnostics, and the need for collaboration, policy alignment, and data systems integration.
Dr. Jain concluded,
“India is uniquely positioned to lead globally in precision medicine. Enhanced NGS, digital diagnostics, and AI innovations are redefining possibilities — but collaboration, policy alignment, and unified data systems are the key to real progress.”

The day continued with Panel 1: Implementation of Precision Medicine in India: Infrastructure, Policy, and Ethics, a robust session focused on integrating precision medicine into India’s existing healthcare framework. This panel was graced by Dr. Anushree Gupta, Additional Professor and Head of the Department of Biotechnology at AIIMS, New Delhi; Dr. R. Ranga Rao, Chairman of Paras Cancer Centre, Paras Health Gurugram; Dr. Vijay Arora, Principal Director of Internal Medicine at Yashoda Medicity; and Dr. Manisha Khurana, Founder of NextEdge-Precision Medicine Insights. Together, they discussed policy and regulatory frameworks, ethical considerations in genetic testing and patient data privacy, and the importance of ecosystem building for the future of precision medicine in India.

The event also featured insightful presentations, including one by Dr. Bichitra Biswal, Scientist G at the National Institute of Immunology (NII), who delivered a thought-provoking session on the implementation landscape. Dr. Dheeraj Gautam, Director - Lab & Pathology at Medanta the Medicity, Gurugram, followed with a presentation on “Early NSCLC Diagnosis”, offering perspectives on how precision diagnostics is revolutionizing oncology. Dr. Prudwidhar Sriperumbudhuru, Director - Medical Affairs at Miltenyi Biotec, provided an industry viewpoint, and Dr. Vikash Kumar, Senior Product Specialist at Thermo Fisher Scientific, discussed advancements in precision oncology, bringing in a clinical sequencing perspective.

Panel 2: Integrating Digital Pathology & Genomic Profiling into Precision Medicine: Transforming Diagnostic Workflows brought together Dr. Dheeraj Gautam, Dr. Nita Radhakrishnan, Additional Professor & HOD of Pediatric Hematology-Oncology at the Post Graduate Institute of Child Health, Noida; Dr. Ravi Gaur; Dr. Ashwin Dalal, Head of the Diagnostics Division at the Centre for DNA Fingerprinting and Diagnostics, Hyderabad; Dr. Priyanshu Mathur, Head of the Division of Medical Genetics at SMS Medical College, Jaipur, and State Nodal Officer for Rare Diseases - Rajasthan; and Dr. Luv Bansal, Consultant Neurologist at Yashoda Super Speciality Hospitals. This panel explored how digital pathology, AI, and genomic profiling are enhancing diagnostic precision and enabling personalized care.

The momentum carried forward into Panel 3: Revolutionizing Treatment: The Future of Cell & Gene Therapy in Rare Diseases, Oncology, and Pharmacogenomics. Esteemed panelists included Dr. Ratna Dua Puri, Chairperson of the Institute of Medical Genetics & Genomics at Sir Ganga Ram Hospital; Dr. Gagan Saini, Vice Chairman & Head of Radiation Oncology at Yashoda Medicity; Dr. Sangram Keshari Samal, Scientist D at the Indian Council of Medical Research, Government of India; Priya Kapoor G Hingorani, Managing Director, India & South East Asia at Miltenyi Biotec; Dr. Vineet Talwar, Director of Medical Oncology at Rajiv Gandhi Cancer Institute & Research Centre, Delhi; and Dr. Vamshi Krishna Thamtam, Head of Genomics & Clinical Cytogenomics at Dr Lal Pathlabs. The panel highlighted cutting-edge therapies like CAR T-cell therapy, pharmacogenomics, and AI-driven innovations that are redefining treatment outcomes in India.

The afternoon session featured Panel 4: Backing NexGen Innovations — The Role of AI and Data Science for Precision Medicine, where Dr. Prashant Kumar, Chief Scientific Officer at Datar Cancer Genetics; Dr. Gautam Das, Co-Founder & CEO of miBiome Therapeutics; Dr. Amrit Kaur Kaler, Consultant in Molecular Pathology at Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai; Vandana Wadhwa, Chief Operating Officer at Oncquest Laboratories; and Dr. Debjani Saha, AGM- Marketing at Premas Life Sciences, came together to discuss the application of AI in clinical decision-making, AI-led drug discovery, and the challenges of implementing such solutions in India.

In Panel 5: Empowering Patients in Precision Medicine: Informed Decisions, Equity, and Education, the focus shifted to patient empowerment, access, and education. The distinguished panel comprised Padma Shri Dr. P. K. Julka, Vice Chairman of Oncology at Max Institute of Cancer Care, Delhi; Dr. Jyoti Wadhwa, Vice Chairperson & HOD of Medical Oncology & Hematology at Paras Health, Gurugram; Jyotsna Govil, Chairperson of the Indian Cancer Society- Delhi Branch; Dr. Aparna Dhar, Director of Hereditary, Precision Oncology and Genetic Counseling at Max Healthcare; Dr. Kanika Sood Sharma, Director & Clinical Lead of Radiation Oncology at Dharamshila Narayana Superspeciality Hospital, Delhi; and Dr. Shubnum Singh, Principal Advisor-Healthcare, Confederation of Indian Industry (CII) and Advisor & Governing Board Member, Health Sector Skills Council. This meaningful dialogue emphasized informed decision-making, public awareness, and advocacy-driven initiatives in precision medicine.

The concluding conversations included engaging one-on-one sessions such as “Biomarkers in Immunotherapy” with Dr. Bhuvan Chugh, Principal Consultant – Medical Oncology at Max Healthcare, in conversation with Dr. Manisha Khurana, Founder of NextEdge. Another insightful exchange titled “Genes, Data & the Human Heart: A New Era of Cardiology” featured Dr. T.S. Kler, Chairman of Cardiology at BLK-Max Hospital, Delhi, in conversation with Dr. Debjani Saha from Premas Life Sciences.

The evening culminated in a magnificent Awards Ceremony — a highlight of the conclave — where the remarkable contributions of healthcare pioneers and organizations were honoured. The ceremony was graced by Shri Ravinder Singh, Hon’ble Minister – Social Welfare, SC & ST Welfare, Cooperative, & Election, Government of Delhi. Shri Ravinder Singh felicitated the award winners, congratulating them for their exceptional work in transforming India’s healthcare landscape through precision medicine. His address radiated warmth and optimism, as he applauded the honorees’ tireless efforts and extended his best wishes for their future endeavours, emphasizing the importance of such groundbreaking work for India’s healthcare future.

“Doctors are no less than God, as every patient approaches them with hope, trust, and just one question — ‘Main thik toh ho jaunga na?’ (Will I recover?). As we move towards our vision of Aatmanirbhar Bharat 2027 and aim to become a global leader, the highly qualified doctors seated before me will play a crucial role in safeguarding the health of our people. A healthy nation is the foundation of national progress and prosperity. I extend my heartfelt congratulations to all the winners and best wishes to the doctors and healthcare leaders present here for their invaluable contributions.”

Precision Med India 2025 was not just a conclave — it was a movement of ideas, collaboration, and recognition. It set a new benchmark in precision healthcare dialogue in India, uniting academia, healthcare providers, policymakers, and industry leaders for a smarter, more inclusive, and patient-centric healthcare future.